世之源生物科技有限责任公司

Products

Practicing Green Pharmaceutical Manufacturing
Contributing to Healthy China

UB-221
UB-421
UB-621

UB-221

Common allergic diseases are closely associated with IgE antibodies, which play a major role in allergic reactions. When the human body is exposed to allergens, the immune system produces a large amount of IgE antibodies

Explore more

UB-421

In addition to its potential for functional cure, UB-421 demonstrates remarkable efficacy in treating patients with multidrug-resistant HIV

Explore more

UB-621

UB-621 is a groundbreaking innovative monoclonal antibody that makes the suppression of recurrent genital herpes possible

Explore more

About Us

Focusing on Unmet Medical Needs
Bringing Hope of Treatment to Patients.

Genesis Life Science was established in October 2020, focusing on the innovative development of monoclonal antibody (mAb) drugs. The company drives domestic clinical filings and subsequent clinical trial progress, while also carrying out related clinical sample testing. Looking ahead, we aim to achieve the full commercialization of biopharmaceuticals. With our internal research strength and the support of cross-disciplinary expert teams, we are determined to become a leading biopharmaceutical enterprise in China.

Explore Genesis Life Science

Investor Relations

Warm Partnerships
Charting a New Course
in Pharma Investment

In the booming tide of the pharmaceutical sector, we consistently value the strong bond with investors. Guided by sincerity, we aim to forge a communication bridge, jointly explore growth opportunities, and embark on a new journey side by side.

Explore more

点击前往